Evaluation of programmed cell death ligand 1 (PD-L1) expression can be made on both resection specimens and diagnostic biopsies; however, more than 30% of patients with advanced non-small cell lung cancer (NSCLC) do not have adequate histologic material to perform PD-L1 assays and require additional biopsies. In addition, in our practice, more than 16% of cases have cytological smears as the only available material. Our aim was to validate the PD-L1 immunocytochemistry assay on cytological smears and compare its accuracy with the results obtained from tissue cores and whole tumor sections using the clinically relevant cutoff of 50%. METHOD: We compared the PD-L1 staining results of cytological smears to those from tissue cores or whole sections in 50 and 53 NSCLC cases, respectively, using the SP263 assay after scanning hematoxylin and eosin slides. RESULTS: We found an overall agreement of 90.6% between cytological smears and whole sections; specifically, we found absolute concordance between smears with PD-L1 expressed in <10% and ≥50% of cells and whole sections with PD-L1 expressed in <50% and ≥50% of cells, respectively. In addition, slightly lower diagnostic accuracy was found for the cytological smears in comparison with the tissue cores, but the difference was not statistically significant. We found excellent intraobserver and good interobserver agreement in the evaluation of PD-L1 on smears. CONCLUSION: Immunocytochemistry on cytological smears is a reliable method for determination of PD-L1 at the 50% cutoff when positive cells are <10% or ≥50%; for cases showing PD-L1 expression in 10% to 49% of cells, additional tissue sampling may be necessary.
INTRODUCTION
Lung cancer is one of the most common causes of cancer-related mortality worldwide; non-small cell lung carcinoma (NSCLC) represents more than 85% of cases, and two thirds are diagnosed at an advanced stage, with a 5-year survival rate of <15%. Although chemotherapy regimens have not changed in the last 15 years, the discovery of driver alterations of oncogenes such as EGFR mutations and ALK translocations, together
Cancer Cytopathology January 2019 with the discovery of tyrosine-kinase inhibitors for EGFR (gefitinib, erlotinib, afatinib, osimertinib) and ALK (crizotinib, alectinib, ceritinib, brigatinib), improved the survival of patients with such genetic alterations. These targetable alterations are seen in <15% of patients with NSCLC in Caucasian cohorts, although this figure could reach 50% in Asian cohorts. 1 More recently, improvements in the understanding of the relationships between cancer and the immune system and, more specifically, the discovery of immune response's inhibitory checkpoints have offered new therapeutic opportunities for larger numbers of patients.
Programmed cell death 1 (PD1) is an inhibitory receptor originally identified in T lymphocytes that, upon interaction with its ligand PD-L1, delivers inhibitory signals that downregulate T cell function. Under physiological conditions, this interaction leads to peripheral T cell tolerance, whereas in cancer patients it may impair T cell responses against tumor cells. [2] [3] [4] In this context, immunotherapy with checkpoint inhibitors that disrupt the PD1/PD-L1 interaction has proven highly effective in different tumor types, representing a true revolution in cancer therapy. [5] [6] [7] Pembrolizumab is an anti-PD1 humanized monoclonal antibody that was recently granted US Food and Drug Administration approval after clinical trials conducted in patients with advanced NSCLC on the basis of the PD-L1 expression in viable tumor cells assessed with a validated assay. Specifically, the KEYNOTE-010 trial demonstrated that pembrolizumab prolonged the overall survival in previously treated patients whose tumors expressed PD-L1 in at least 1% of cells. 8 Moreover, the KEYNOTE-001 and the KEYNOTE-024 trials showed significantly longer progression-free survival and overall survival for previously untreated patients with NSCLC expressing PD-L1 in at least 50% of cells, initiating the approval of pembrolizumab as a first line of therapy. 9, 10 According to trial indications, PD-L1 expression evaluation can be made on both the resection specimens or diagnostic biopsies; 9 however, in more than 30% of patients with advanced NSCLC, adequate tumor tissue is not available, and tissue biopsies are needed in order to obtain histologic material suitable for immunohistochemistry. 11 In a proportion of these patients, only cytological specimens may be available; in this setting, different studies have evaluated the reliability of cell blocks for the determination of PD-L1 expression.
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However, even with accurate on-site evaluation of cytological material collected from fine needle aspiration (FNA) procedures, it is not always possible to obtain adequate cell blocks suitable for immunocytochemistry, and only cytologic smears would remain available for PD-L1 assessment. For this reason, the goal of this study was to validate PD-L1 immunocytochemistry on cytologic smears. In addition to a pure technical validation, we wanted to evaluate the reliability of such a method at the cutoff of 50% in comparison with whole tumor sections from the resection specimens, which is considered the standard criterion.
As a secondary endpoint, we compared the diagnostic accuracy of cytologic smears with tissue cores as a surrogate for diagnostic biopsies, which represent the material most frequently available in clinical practice.
MATERIALS AND METHODS

Study Design
The cohort used for this study was described in a recent article from our group 17 in which we compared PD-L1 expression (clone SP263) between core biopsies from tissue microarrays (TMAs) and corresponding whole tumor sections in 268 cases of NSCLC, considering PD-L1 expression value on whole sections as the reference. From this cohort, we selected all cases with available cytological material collected during specimen processing after surgical resection. Cytologic smears were obtained using a standard approach consisting of 4 FNA procedures with 27-guage needles, promptly put on slides, fixed in 95% alcohol, and stained with hematoxylin and eosin (HE) for rapid diagnostic assessment as an adjunct to frozen and/or definitive histology.
Samples to be selected were categorized a priori in 3 groups on the basis of PD-L1 positivity on whole tumor sections according to clinically relevant cutoffs of <1%, 1% to 49%, and 50%, corresponding to the thresholds we use in routine clinical practice.
Cases before January 1, 2012, were excluded; moreover, since cases with PD-L1 expression ≥50% were the smallest in number, we collected all cases with PD-L1 ≥50% on whole sections with available cytological smears up to December 31, 2017. A minimum Cancer Cytopathology January 2019 number of 10 such cases was defined for the study to be completed. On the basis of the number of cases with PD-L1 ≥50% on whole sections, we then selected cases with PD-L1 <1% and 1 to 49% with a ratio of 1.5 and 1.2, respectively, which correspond approximately to the proportion that we observe routinely in our clinical practice.
All experiments were conducted according to the principles expressed in the Declaration of Helsinki.
Immunocytochemistry HE-stained smears were scanned using a Ventana iScan HT instrument and then destained and restained with PD-L1 as follows: slides were immersed in acetone (3 minutes) and xylene (10 minutes) to remove the coverslip; the smears were then rehydrated with alcohol with decreasing concentration and immersed in distilled water. The slides were stained with PD-L1 (clone SP263, Ventana Medical Systems, Tucson, Arizona) on an automated staining platform (Benchmark ULTRA; Ventana Medical Systems) inclusive of antigen retrieval with CC1 solution (24 minutes) and incubation time with primary antibody (1 hour). An OptiView DAB IHC detection kit (Ventana Medical Systems) and an OptiView amplification kit (Ventana Medical Systems) were used according to the manufacturer's recommendations for the visualization of the primary anti PD-L1 antibody.
Scoring
PD-L1 evaluation on smears was performed by a pathologist who was blind to the results of the whole tumor sections and who uses clone SP263 in clinical practice. Sections were scored based on the percentage of tumor cells showing membranous positivity, irrespective of staining intensities; at least 100 cells had to be present for the smears to be considered adequate. Macrophages were used as an internal control and samples of neoplastic tissue diffusely positive and completely negative for PD-L1 were used as external control.
The percentage of positive tumor cells were recorded with 10% increments. Concordance with the corresponding resection specimens (whole tumor sections) were evaluated with various cutoffs.
During the evaluation of the cytologic smears, some cases were easily classified as negative when PD-L1 was completely absent or only focally present, whereas other cases required a more accurate assessment through comparison with previously scanned HE stains. This was important to differentiate tumor cells from lymphocytes or macrophages and to distinguish between membrane and cytoplasmic staining.
To evaluate the intra-and interobserver variability, a reevaluation of the specimens was performed by the same pathologist after a washout period of 2 months and by a second pathologist with the same experience with clone SP263.
Statistical Analysis
The comparative analysis of PD-L1 expression on cytologic smears and biopsies with respect to whole tumor sections (considered as the standard criterion) was expressed in terms of overall agreement, sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), and receiver operating characteristic area under the curve. Pearson correlation was used when considering PD-L1 expression as a continuous variable. To compare the intra-and interobserver agreement, overall percent agreement and Cohen's kappa were calculated. A Fisher exact test or chi-square test were used to statistically compare the categorical variables; P < .05 was considered significant. Calculations were performed using STATA version 14 (StataCorp, College Station, Texas).
RESULTS
Study Cohort
Overall, we collected 55 cases with cytological smears and paired whole sections; 50 of these cases had 5 cores of tissue microarrays as well. 17 The clinico-pathological features of the patients in this study were as follows: 39 patients were men (71%) and 16 were women (29%), with a median age of 71 years (range, 51-83 years). There were 45 cases (81.8%) of adenocarcinoma, 6 cases (10.9%) of squamous cell carcinoma and 4 cases (7.3%) of large cell carcinoma. In 37 cases (67.2%), the tumor diameter was <3 cm (T1). Lymph nodes were negative (N0) in 37 cases (67.2%), whereas they were metastatic (N ≥1) in 13 cases (23.6%); in the remaining 5 cases (9.2%), lymph node status was unknown (Nx). For 37 cases (67.2%), the material had been collected between 2016 and 2017; the remaining 18 cases (32.8%) were collected between 2012 and 2015.
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PD-L1 Evaluation on Cytologic Smears Compared With Whole Sections and TMA Cores
In a few cases, PD-L1 immunostaining showed focal nuclear and cytoplasmic granular staining that was correctly interpreted as artifactual; in 2 cases, staining was diffuse and was therefore excluded (Fig. 1) . In the remaining 53 cases analyzed, PD-L1 expression on the whole tumor sections showed the following results: 15 cases (28.3%) were positive (PD-L1 ≥50%), and 38 cases (71.7%) were negative (PD-L1 <50%). The corresponding cytologic smears revealed that 10 cases (18.9%) were positive (PD-L1 ≥50%) and 43 cases (81.1%) were negative (PD-L1 <50%) (Fig. 2) .
When considering PD-L1 expression as a continuous variable, the Pearson's correlation coefficient was r = 0.90.
At the cutoff of 50%, the comparison between the cytologic smears and whole sections showed a concordance rate of 48/53 cases (90.6%) with 5 false-negative cases (sensitivity, 66.7%; NPV, 88.4%; ROC area, 0.83) and without false positive cases (specificity, 100%; PPV, 100%) ( Table 1 ). In general, we found higher cytoplasmic staining in the tumor cells on the cytologic smears compared with the histologic sections, but this did not interfere with the interpretation (Fig. 3) .
Concordance between cytologic smears with the corresponding resection specimens was then evaluated with various cutoffs. We found that PD-L1 expression in <10% and ≥50% of cells on cytologic smears were absolute predictors of negative (<50%) and positive (≥50%) expression in the resections, respectively. Of the 14 cases with PD-L1 expressed in 10-49% of cells on cytological smears, on whole sections 9 cases (64.3%) showed PD-L1 expression in <50% of cells while 5 cases (35.7%) showed PD-L1 expression in ≥50% of cells. (Table 2 , Fig. 4) .
The 5 cases that were scored PD-L1 <50% on the cytological smears and ≥50% on the whole sections showed some peculiarities: case #1 was the oldest of the series (February 2012) with an archival time of more than 5 years; case #9 was difficult to evaluate because the value was close to 50% on the cytological smear; cases #38 and #52 showed diffuse necrosis and case #50 showed a PD-L1 value = 50% on the whole section. 
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Regarding 1% cutoff, the agreement between the cytologic smears and whole section did not reach 90%, with 43/53 cases being concordant (81.1%): 5 cases were false-negatives (sensitivity, 84.4%; NPV, 76.2%), whereas 5 cases were false-positives (specificity, 76.2%; PPV, 84.4%).
In 50 of the 53 cases, the paired core biopsies were also available; for scoring purposes, the mean PD-L1 value was considered as the final score when there were discrepant results across the different cores.
The TMA core biopsies and whole sections showed a concordance rate of 46/50 cases (92%) with 4 false-negative cases (sensitivity, 69.2%; NPV, 88.3%) and no false-positive cases (specificity, 100%; PPV, 100%; ROC area, 0.84).
The comparison between the cytologic smears and the core biopsies showed concordance in 44/50 cases (88%) at the cutoff of 50%: 3 cases resulted negative on the smears and positive on the core biopsies while 3 cases were negative on the core biopsies and positive on the smears.
The comparison of the diagnostic accuracy between TMA core biopsies and cytologic smears among the corresponding whole sections showed slightly lower values in terms of concordance, sensitivity, specificity, NPV, and area under the curve for the smears, but such differences were not statistically significant (P = .13 for the difference in the area under the curve) ( Table 3) .
Intra-and Interobserver Variability
When we considered 3 categories of PD-L1 expression on the cytological smears (<10%, negative; 10%-49%, uncertain; ≥50%, positive), the intraobserver concordance was 98.1% (Cohen's κ = 0.94), with 1 case categorized differently (negative [<10%] instead of uncertain [10%-49%]). Regarding interobserver agreement, concordance was 90.5%, (Cohen's κ: 0.69), with 4 cases Cancer Cytopathology January 2019 discordant between negative (<10%) and uncertain (10%-49%) and 1 case discordant between uncertain (10%-49%) and positive (≥50%).
DISCUSSION
Immunotherapy targeting the PD1/PD-L1 axis with specific inhibitors represents a true revolution in the field of oncology and is a starting point of a new paradigm for the treatment of tumors. 5 Accordingly, predicting which patients will respond to checkpoint inhibitor therapy is a major issue, particularly for NSCLC. So far, prediction has been based primarily on immunohistochemical evaluation of PD-L1 expression on tumor cells. Moreover, although different studies have found significant correlations between the expression of PD-L1 and the response to therapy in different tumor types, others have not. Indeed, responses have also been observed in patients whose tumors were classified as PD-L1-negative. 18 This can be due to different reasons:
newly discovered biological complexity underpinning the tumor-immunity interplay, 19 PD-L1 expression heterogeneity, 20 different clones, 21, 22 and inter-and intraobserver variability. 17, 23 Notwithstanding these limitations, the determination of PD-L1 expression in neoplastic cells is a necessary condition for the treatment of NSCLC with pembrolizumab: initially used in a second-line setting for NSCLC expressing PD-L1 in at least 1% of the sample, its indication has been subsequently extended to first-line treatment as a monotherapy in NSCLC expressing PD-L1 in at least 50% of neoplastic cells. Cancer Cytopathology January 2019
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In this regard, the 50% cutoff is the most relevant because it is used to select patients with advanced NSCLC for immunotherapy with pembrolizumab as first-line treatment. The 1% cutoff is used to select patients for immunotherapy with pembrolizumab as a second-line treatment, although other immunotherapies (eg, nivolumab) can be used independently of PD-L1 expression status in this setting.
According to trial indications, evaluation may be performed on both resection specimens and small biopsies. 9 However, not all patients end up having histological biopsies: in more than 30% of cases, only cytologic specimens obtained from FNA procedures are available. 11 However, the use of cytology samples for determination of PD-L1 is not currently advocated due to lack of validation. On the other hand, immunostaining of tumor cells on cytology samples represents a standard diagnostic practice and is performed routinely in many laboratories; therefore, PD-L1 determination on cytologic samples may be feasible in principle, provided that it is validated. 11 In this regard, a few studies have addressed this issue by using cell blocks; [12] [13] [14] [15] [16] however, it is not always possible to obtain cell blocks with quantitatively and qualitatively sufficient material to perform PD-L1 determination, despite on-site evaluation of cytologic aspirates during the diagnostic procedure. Specifically, in our clinical practice, the chance of having cytologic smears as the only available diagnostic material on which to perform predictive tests occurs in approximately 16% of cases.
For this reason, in this study, we assessed whether PD-L1 immunostaining on cytologic smears can be a Abbreviations: NPV, negative predictive value; PPV, positive predictive value; ROC, receiver operating characteristic.
Cancer Cytopathology January 2019 reliable method for PD-L1 quantification by comparing staining results on smears with whole tumor sections using a validated, CE-marked assay (SP263). Moreover, we wanted to compare the diagnostic accuracy of cytologic smears with tissue cores as surrogates for diagnostic biopsies, which represent the materials most frequently encountered in clinical practice.
At an analytical level, the evaluation of cytologic smears is difficult due to the lack of morphological and architectural landmarks; such impediments can be even more pronounced if the corresponding HEstained slide is missing. To avoid this situation, we preventively scanned the smears that had been selected for PD-L1 staining. The parallel evaluation of both HE and PD-L1 staining on the same smears allowed a more confident interpretation of the PD-L1-positive cells; otherwise, it would have been difficult to distinguish inflammatory from neoplastic cells. We therefore assessed the concordance in terms of PD-L1 staining between the cytologic smears and paired histological specimens in 55 NSCLC cases collected between 2012 and 2017.
Two cases were discarded because the smears showed a diffuse granular nuclear-cytoplasmic PD-L1 positivity, which was correctly interpreted as artifactual by the pathologist. The evaluation of the remaining 53 cases showed an overall agreement of 90.6% at the 50% cutoff, in line with the value of at least 90% in terms of the general agreement required by the College of American Pathologists guidelines for immunohistochemical assays. 24 However, despite a specificity of 100%, we obtained unsatisfactory results in terms of sensitivity (67.7%), with 5 false-negative cases. Notably, falsenegative cases were not uniformly distributed within the cases with less than 50% of cells stained with PD-L1 on smears. In fact, by stratifying this group into 2 categories (PD-L1 <10% and 10%-49%), we observed that all cytologic smears with <10% of stained cells corresponded to the whole sections with PD-L1 values <50%. Instead, cytologic smears with 10% to 49% of stained cells showed a false negative rate of 35% in comparison with whole sections; therefore, in these cases, it is reasonable to collect additional material. Regarding the 1% cutoff, the agreement between the cytologic smears and whole section was less satisfactory given that it did not reach 90%, with a concordance of 81.3%.
In clinical practice, the determination of PD-L1 on histological material is mostly performed on biopsy specimens rather than surgical resections. Given the heterogeneity of PD-L1 expression within tumors, there is often a lack of concordance between the results obtained from biopsies and those obtained from surgical resection specimens. 17, 20 Therefore, we investigated whether a substantial difference between cytologic smears and core biopsies (as a surrogate of diagnostic biopsies) exists in terms of reliability for PD-L1 determination, considering whole tumor sections as the reference. We found slightly lower diagnostic accuracy for the cytologic smears in comparison with core biopsies, but the difference was not statistically significant. Because a recent study had reported some intra-and interobserver discordance for PD-L1 evaluation on histological material, 25 we assessed the degree of intra-and interobserver variability for PD-L1 quantification on cytological smears. We found excellent intraobserver agreement (98.1%; Cohen's κ = 0.94) and good interobserver agreement (90.5%; Cohen's κ = 0.69).
Only a few studies have evaluated cytology in comparison with surgical specimens for PD-L1 determination using 50% positive cells as the cutoff; however, in most studies, the investigators assessed cell blocks only. Among these, Sakakibara et al 13 compared PD-L1 expression between cell blocks and paired histological specimens in 6 cases and found concordance in 5 cases (83%) using clone EPR116; in 5 of the 6 cases, lymph node metastasis was also available, and the results were fully concordant with those obtained on cell blocks. In another study, Skov et al 14 PD-L1 expression concordance between cytologic smears and biopsy specimens using clone 22C3. In this study, the authors found very high concordance between smears and biopsy specimens, with no differences in terms of PD-L1 expression at 1% and 50% cutoffs. On the other hand, the concordance between biopsy specimens and cell blocks was less satisfactory, with 4 discordant cases at 50% cutoff and 1 discordant case at 1% cutoff. In our study, the concordance rate between smears and whole tumor sections was lower than that reported by Noll et al. There are some differences between our study and the study by Noll et al: our comparison was performed using whole tumor sections and not biopsy specimens, and it is known from the literature that important differences exist between biopsies and surgical resections in terms of PD-L1 expression due to its heterogeneity. 20, 27 Furthermore, we used a different assay (SP263) and important discrepancies in terms of PD-L1 expression between SP263 and 22C3 have been reported. 21, 22 Our study has some limitations, including the fact that the cytology samples were obtained directly from the surgical specimens; therefore, it could be possible that, even if a small (27-guage) needle was used, the smears yielded more cells than the average cytologic specimens obtained during standard diagnostic procedures. Moreover, we used the CE-marked SP263 clone because the platform available at our institution is a Ventana Medical Systems instrument. In this regard, because data about the interchangeability with other clones are discordant, the results obtained in our study may not necessarily be reproducible with other PD-L1 assays such as 22C3, 28-8, and SP142.
Therefore, this study should be considered as an exploratory analysis with the primary objective to assess the technical feasibility of PD-L1 expression evaluation on cytologic smears and to address its reliability in comparison with resection specimens. We therefore believe that our observations should be ideally followed by a validation study encompassing a larger cohort of real-world cases with preoperative FNA cell smears and the corresponding resection specimens.
In conclusion, we provide a demonstration of the feasibility of PD-L1 status determination with clone SP263 on cytologic smears with an appropriate immunostaining protocol. Moreover, due to some precautions in the analytical phase, such as slide scanning, we report an overall concordance of >90% between stained smears and whole sections. Specifically, we found good agreement between smears with PD-L1 expressed in <10% and ≥50% of cells and whole tumor sections with PD-L1 expressed in <50% and ≥50% of cells, respectively. Concerning the comparison between the cytological smears and tissue cores, we found slightly lower values in terms of the concordance with the paired whole tumor sections for the cytological smears, but the difference was not statistically significant. Finally, we showed excellent intraobserver agreement and good interobserver agreement in the evaluation of PD-L1 in the cytological smears.
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